Loading…
Employees: 625
Size Gyre Therapeutics (GYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $505M, the 2689th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.76 on 6 Nov 2026.
Performance Over six months the shares fell 36.3%, against -18.1% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 16.8% over the last twelve months (peer median +7.0%); the operating margin is -11.4% (peer median 10.0%).
Valuation It trades at 4.1× enterprise value to sales against a peer median of 3.9× (8th most expensive of 18).
Capital Return on invested capital runs 24.6 points below its cost of capital (17.5% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $119M | $117M | $106M | $113M | $102M |
| Revenue growth | — | +10% | -7% | +11% | — |
| Gross profit | $113M | $111M | $102M | $109M | $97.5M |
| EBITDA | -$10.1M | $14.0M | $17.8M | $20.3M | $10.3M |
| Net income | -$17.4M | $5.03M | $12.1M | -$92.9M | $2.30M |
| Free cash flow | -$15.4M | -$1.67M | -$6.49M | $17.4M | $5.69M |
| Capital expenditure | $2.29M | $1.92M | $3.13M | $8.59M | $5.00M |
| Total debt | $3.42M | $939,000 | $1.60M | $409,000 | $613,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GYRE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.6% | -7.2% | lowest of 21 |
| 6-month return | -36.3% | -18.1% | 4th lowest of 20 |
| Distance from 52-week high | -47.9% | -41.9% | 8th lowest of 21 |
| Revenue growth (TTM) | +16.8% | +7.0% | 6th highest of 19 |
| Operating margin | -11.4% | 10.0% | 6th lowest of 18 |
| EV / Sales | 4.1× | 3.9× | 8th most expensive of 18 |
| ROIC minus cost of capital | -24.6 pp | -2.1 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |